Marina Biotech this week said that a nine-month non-human primate toxicology study of its familial adenomatous polyposis treatment CEQ508 has shown the drug to be safe after repeated administration.

In the study, 18 cynomolgus monkeys received daily oral doses of either CEQ508 or a control agent for 281 days. No drug-related adverse responses were found in regards to clinical observation, body weights and temperatures, serum chemistry, coagulation, hematology, urinalysis, cytokines, or gross pathology, Marina said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.